Literature DB >> 28687356

Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.

Marta Betti1, Elisabetta Casalone2, Daniela Ferrante3, Anna Aspesi1, Giulia Morleo1, Alessandra Biasi1, Marika Sculco1, Giuseppe Mancuso4, Simonetta Guarrera2, Luisella Righi5, Federica Grosso6, Roberta Libener7, Mansueto Pavesi8, Narciso Mariani9, Caterina Casadio10, Renzo Boldorini4, Dario Mirabelli11, Barbara Pasini12, Corrado Magnani13, Giuseppe Matullo12, Irma Dianzani14.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer caused by asbestos exposure. An inherited predisposition has been suggested to explain multiple cases in the same family and the observation that not all individuals highly exposed to asbestos develop the tumor. Germline mutations in BAP1 are responsible for a rare cancer predisposition syndrome that includes predisposition to mesothelioma. We hypothesized that other genes involved in hereditary cancer syndromes could be responsible for the inherited mesothelioma predisposition. We investigated the prevalence of germline variants in 94 cancer-predisposing genes in 93 MPM patients with a quantified asbestos exposure. Ten pathogenic truncating variants (PTVs) were identified in PALB2, BRCA1, FANCI, ATM, SLX4, BRCA2, FANCC, FANCF, PMS1 and XPC. All these genes are involved in DNA repair pathways, mostly in homologous recombination repair. Patients carrying PTVs represented 9.7% of the panel and showed lower asbestos exposure than did all the other patients (p = 0.0015). This suggests that they did not efficiently repair the DNA damage induced by asbestos and leading to carcinogenesis. This study shows that germline variants in several genes may increase MPM susceptibility in the presence of asbestos exposure and may be important for specific treatment.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Asbestos exposure; DNA repair genes; Germline mutation; Homologous recombination repair; Mesothelioma

Mesh:

Substances:

Year:  2017        PMID: 28687356     DOI: 10.1016/j.canlet.2017.06.028

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  26 in total

1.  Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Authors:  Vasiliki Panou; Meghana Gadiraju; Arthur Wolin; Caroline M Weipert; Emily Skarda; Aliya N Husain; Jyoti D Patel; Buerkley Rose; Shannon R Zhang; Madison Weatherly; Viswateja Nelakuditi; Amy Knight Johnson; Maria Helgeson; David Fischer; Arpita Desai; Nanna Sulai; Lauren Ritterhouse; Oluf D Røe; Kiran K Turaga; Dezheng Huo; Jeremy Segal; Sabah Kadri; Zejuan Li; Hedy L Kindler; Jane E Churpek
Journal:  J Clin Oncol       Date:  2018-08-16       Impact factor: 44.544

2.  Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.

Authors:  Raffit Hassan; Betsy Morrow; Anish Thomas; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Meghana Gadiraju; Vasiliki Panou; Shaojian Gao; Idrees Mian; Javed Khan; Mark Raffeld; Snehal Patel; Liqiang Xi; Jun S Wei; Mary Hesdorffer; Jingli Zhang; Kathleen Calzone; Arpita Desai; Emerson Padiernos; Christine Alewine; David S Schrump; Seth M Steinberg; Hedy L Kindler; Mary-Claire King; Jane E Churpek
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

Review 3.  Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Authors:  Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass
Journal:  CA Cancer J Clin       Date:  2019-07-08       Impact factor: 508.702

Review 4.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

5.  Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.

Authors:  Marjorie G Zauderer; Gowtham Jayakumaran; Mariel DuBoff; Liying Zhang; Jasmine H Francis; David H Abramson; Andrea Cercek; Garrett M Nash; Alexander Shoushtari; Paul Chapman; Sandra D'Angelo; Angela G Arnold; Beth Siegel; Megan Harlan Fleischut; Andy Ni; Andreas Rimner; Valerie W Rusch; Prasad S Adusumilli; William Travis; Jennifer L Sauter; Ahmet Zehir; Diana Mandelker; Marc Ladanyi; Mark Robson
Journal:  J Thorac Oncol       Date:  2019-07-16       Impact factor: 15.609

Review 6.  The genetic susceptibility in the development of malignant pleural mesothelioma.

Authors:  Ombretta Melaiu; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

7.  A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.

Authors:  Sandra Pastorino; Yoshie Yoshikawa; Harvey I Pass; Mitsuru Emi; Masaki Nasu; Ian Pagano; Yasutaka Takinishi; Ryuji Yamamoto; Michael Minaai; Tomoko Hashimoto-Tamaoki; Masaki Ohmuraya; Keisuke Goto; Chandra Goparaju; Kavita Y Sarin; Mika Tanji; Angela Bononi; Andrea Napolitano; Giovanni Gaudino; Mary Hesdorffer; Haining Yang; Michele Carbone
Journal:  J Clin Oncol       Date:  2018-10-30       Impact factor: 44.544

8.  Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma.

Authors:  Marieke Hylebos; Ken Op de Beeck; Jenneke van den Ende; Patrick Pauwels; Martin Lammens; Jan P van Meerbeeck; Guy Van Camp
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

9.  Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.

Authors:  Gökçen Ömeroğlu Şimşek; İsmail Ağababaoğlu; Duygu Dursun; Selver Özekinci; Pınar Erçetin; Hülya Ellidokuz; Safiye Aktaş; Duygu Gürel; İlhan Öztop; Atila Akkoçlu
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-01-23       Impact factor: 0.332

10.  New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.

Authors:  Giovanni Cugliari; Alessandra Allione; Alessia Russo; Chiara Catalano; Elisabetta Casalone; Simonetta Guarrera; Federica Grosso; Daniela Ferrante; Marika Sculco; Marta La Vecchia; Chiara Pirazzini; Roberta Libener; Dario Mirabelli; Corrado Magnani; Irma Dianzani; Giuseppe Matullo
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.